NCT06125028 (LYMFOR) is a Phase 3 clinical trial of [68Ga]Ga-PentixaFor in Marginal Zone Lymphoma, sponsored by Pentixapharm AG.

Who is sponsoring NCT06125028?

NCT06125028 is sponsored by Pentixapharm AG.

What drugs are being tested in NCT06125028?

Interventions in NCT06125028: [68Ga]Ga-PentixaFor, [18F]Fluorodeoxyglucose.

What condition does NCT06125028 study?

NCT06125028 studies Marginal Zone Lymphoma.

Is NCT06125028 still recruiting?

NCT06125028 is currently terminated. Last updated 5 September 2025.

Last reviewed 2025-09-05 · How we verify

NCT06125028: LYMFOR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma

Terminated Phase 3 Last updated 5 September 2025

What this trial tests

Phase 3 trial testing [68Ga]Ga-PentixaFor in Marginal Zone Lymphoma in 13 participants. Terminated before completion.

Timeline

20 May 2024

Primary endpoint
18 July 2025

18 July 2025

Quick facts

Lead sponsor	Pentixapharm AG
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	other
Enrollment	13
Start date	20 May 2024
Primary completion	18 July 2025
Estimated completion	18 July 2025
Sites	12 locations across France, Italy, Austria, Germany, Spain

Drugs / interventions tested

[68Ga]Ga-PentixaFor — full drug profile →
[18F]Fluorodeoxyglucose

Conditions studied

Marginal Zone Lymphoma — all drugs for Marginal Zone Lymphoma →

Sponsor

Pentixapharm AG — full company profile →

Who can join

Adults 18 to 99, any sex, with Marginal Zone Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This will be a pivotal prospective prospective, international, multi-center, comparative, randomized, cross-over, open-label lymphoma diagnostic trial to assess the diagnostic performance and safety of the positron emission tomography (PET) imaging agent \[68Ga\]Ga-PTF) , versus \[18F\]FDG PET/CT imaging, for staging of patients with confirmed marginal zone lymphoma exemplary for CXCR4-positive malignant lymphomas.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Recent Updates of PET in Lymphoma: FDG and Beyond.
Kim SY, Chung HW, So Y, Lee MH, et al · · 2024 · cited 2× · PMID 39595051 · DOI 10.3390/biomedicines12112485
Radiosynthesis and preclinical evaluation of a <sup>68</sup>Ga-labeled tetrahydroisoquinoline-based ligand for PET imaging of C-X-C chemokine receptor type 4 in an animal model of glioblastoma.
Suwattananuruk P, Yaset S, Chotipanich C, Moldes-Anaya A, et al · · 2024 · cited 2× · PMID 39162901 · DOI 10.1186/s41181-024-00290-y
Is CXCR4 Theranostics in Oncologic, Cardiovascular, and Inflammatory Diseases Really Happening?
Hartrampf PE, Werner RA, Higuchi T, Schottelius M, et al · · 2026 · PMID 41819832 · DOI 10.2967/jnumed.125.271153

Verify or expand the search:

Other trials of [68Ga]Ga-PentixaFor

Trials testing the same drug.

NCT07007325 — Prospective Feasibility Pilot Study Evaluating the Value of [68Ga]Ga-PENTIXAFOR PET-CT in Patients With Metastatic Small · EARLY_PHASE1 · not yet recruiting
NCT06871176 — PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Mye · NA · recruiting
NCT06246357 — Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisoli · Phase 2 · recruiting
NCT05321862 — Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple My · Phase 2 · withdrawn
NCT04561492 — Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma · Phase 2 · recruiting

Other recruiting trials for Marginal Zone Lymphoma

Currently open trials in the same condition.

NCT06796998 — Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) · Phase 2 · recruiting
NCT06792825 — HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL · Phase 2 · recruiting
NCT06860880 — Combating Cancer-Related Fatigue: A Personalized Supportive Care Program · NA · recruiting
NCT06636175 — 64Cu-LLP2A for Imaging Hematologic Malignancies · EARLY_PHASE1 · recruiting
NCT06563596 — Epco, Zanu, Ritux for R/R FL or MZL · Phase 2 · recruiting

Other Pentixapharm AG trials

Trials by the same sponsor.

NCT06132737 — [90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients · Phase 1, PHASE2 · recruiting
NCT05222269 — [68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06125028 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pentixapharm AG
Last refreshed: 5 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06125028.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing